[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004021999A3 - Use of histamine h4 receptor modulators for the treatment of allergy and asthma - Google Patents

Use of histamine h4 receptor modulators for the treatment of allergy and asthma Download PDF

Info

Publication number
WO2004021999A3
WO2004021999A3 PCT/US2003/027943 US0327943W WO2004021999A3 WO 2004021999 A3 WO2004021999 A3 WO 2004021999A3 US 0327943 W US0327943 W US 0327943W WO 2004021999 A3 WO2004021999 A3 WO 2004021999A3
Authority
WO
WIPO (PCT)
Prior art keywords
histamine
receptor modulators
asthma
treatment
allergy
Prior art date
Application number
PCT/US2003/027943
Other languages
French (fr)
Other versions
WO2004021999A2 (en
Inventor
Pragnya J Desai
Paul J Dunford
Claudia L Hofstra
Lars Karlsson
Wai-Ping Leung
Ping Ling
Robin L Thurmond
Original Assignee
Janssen Pharmaceutica Nv
Pragnya J Desai
Paul J Dunford
Claudia L Hofstra
Lars Karlsson
Wai-Ping Leung
Ping Ling
Robin L Thurmond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Pragnya J Desai, Paul J Dunford, Claudia L Hofstra, Lars Karlsson, Wai-Ping Leung, Ping Ling, Robin L Thurmond filed Critical Janssen Pharmaceutica Nv
Priority to MXPA05002577A priority Critical patent/MXPA05002577A/en
Priority to EP03794649A priority patent/EP1545596A4/en
Priority to AU2003265961A priority patent/AU2003265961A1/en
Priority to CA002497788A priority patent/CA2497788A1/en
Priority to JP2004534688A priority patent/JP2006510590A/en
Publication of WO2004021999A2 publication Critical patent/WO2004021999A2/en
Publication of WO2004021999A3 publication Critical patent/WO2004021999A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods are disclosed for identifying histamine receptor modulators that affect mast cell or basophil chemotaxis, and the use of such histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of asthma and/or allergic responses, or diseases and/or conditions that are modulated, affected or caused by asthma or allergic responses. Also disclosed is the use of histamine H4 receptor modulators for the prevention, treatment, induction, or other desired modulation of mast cell or basophil chemotactic responses, such as migration to a particular site, or diseases and/or conditions that are modulated, affected or caused by mast cell or basophil chemotaxis.
PCT/US2003/027943 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma WO2004021999A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA05002577A MXPA05002577A (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma.
EP03794649A EP1545596A4 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
AU2003265961A AU2003265961A1 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
CA002497788A CA2497788A1 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma
JP2004534688A JP2006510590A (en) 2002-09-06 2003-09-05 Use of histamine H4 receptor modulators for the treatment of allergies and asthma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40873602P 2002-09-06 2002-09-06
US60/408,736 2002-09-06

Publications (2)

Publication Number Publication Date
WO2004021999A2 WO2004021999A2 (en) 2004-03-18
WO2004021999A3 true WO2004021999A3 (en) 2004-10-07

Family

ID=31978667

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/027943 WO2004021999A2 (en) 2002-09-06 2003-09-05 Use of histamine h4 receptor modulators for the treatment of allergy and asthma

Country Status (6)

Country Link
EP (1) EP1545596A4 (en)
JP (1) JP2006510590A (en)
AU (1) AU2003265961A1 (en)
CA (1) CA2497788A1 (en)
MX (1) MXPA05002577A (en)
WO (1) WO2004021999A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587141A1 (en) * 2004-11-24 2006-06-01 Pfizer Inc. Octahydropyrrolo[3,4-c]pyrrole derivatives
EP1671972A1 (en) * 2004-11-24 2006-06-21 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
WO2007117465A2 (en) 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
EP2298772A1 (en) * 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
KR100954138B1 (en) * 2007-12-31 2010-04-20 부산대학교 산학협력단 An agent comprising adipose tissue?derived stem cells as effective ingredient for prevention and treatment of allergic rhinitis or asthma
EP2201982A1 (en) * 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
JP2012102017A (en) * 2009-03-03 2012-05-31 Astellas Pharma Inc Indole compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085786A2 (en) * 2000-05-05 2001-11-15 Wyeth Human histamine h4 receptor
WO2001092485A1 (en) * 2000-05-31 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
WO2002056871A2 (en) * 2001-01-17 2002-07-25 Pfizer Limited Histamine receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002336273A1 (en) * 2001-03-09 2002-09-24 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
US20030133931A1 (en) * 2001-12-21 2003-07-17 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
BR0314059A (en) * 2002-09-06 2005-07-05 Janssen Pharmaceutica Nv Heterocyclic compounds
JP2006503827A (en) * 2002-09-06 2006-02-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Use of indolyl derivatives to produce drugs for the treatment of allergic rhinitis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085786A2 (en) * 2000-05-05 2001-11-15 Wyeth Human histamine h4 receptor
WO2001092485A1 (en) * 2000-05-31 2001-12-06 Ortho-Mcneil Pharmaceutical, Inc. DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4 SUBTYPE
WO2002056871A2 (en) * 2001-01-17 2002-07-25 Pfizer Limited Histamine receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1545596A4 *

Also Published As

Publication number Publication date
JP2006510590A (en) 2006-03-30
EP1545596A4 (en) 2005-12-28
WO2004021999A2 (en) 2004-03-18
AU2003265961A1 (en) 2004-03-29
EP1545596A2 (en) 2005-06-29
MXPA05002577A (en) 2005-09-20
CA2497788A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2003099195A3 (en) Immunomodulatory compounds and methods of use thereof
DE60328611D1 (en) RUBBER BASED ON CONJUGATED SERVES, PRODUCTION METHOD AND RUBBER COMPOSITION
WO2004018058A3 (en) Compounds, compositions, and methods
WO2003094839A3 (en) Pyrimidinone compounds, compositions and methods
DE602004028934D1 (en) BENZOE4,5THTHIENOE2,3-DIPYRIMIDIN-4-ONE AND ITS THERAPEUTIC USE
ATE479686T1 (en) PYRIDOPYRROLIZINE AND PYRIDOINDOLIZINE DERIVATIVES
WO2001026658A3 (en) Topical nasal treatment using desloratadine
WO2004032852A3 (en) Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2003088903A3 (en) Compounds, compositions, and methods
AU2003270626A1 (en) Magnetically modified electrodes as well as methods of making and using the same
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
WO2004021999A3 (en) Use of histamine h4 receptor modulators for the treatment of allergy and asthma
WO2004006865A3 (en) Compounds, compositions, and methods
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
WO2004032840A3 (en) Compounds, compositions, and methods
WO2006136428A3 (en) Method and composition to treat skin ulcers
AU2003241398A1 (en) Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
WO2004034972A3 (en) Compounds, compositions, and methods
WO2005074655A3 (en) Materials and method for promotion of nerve regeneration
AU2002359459A1 (en) Treating b-cell mediated diseases by modulating dr6 activity
WO2004064741A3 (en) Compounds, compositions, and methods
WO2003057919A3 (en) The use of histamine h4 receptor antagonist for the treatment of inflammatory response
WO2003092669A3 (en) Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac
WO2005042697A3 (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003265961

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004534688

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2497788

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/002577

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003794649

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003794649

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003794649

Country of ref document: EP